Literature DB >> 10733741

Role of CD8+ T cells in endogenous interleukin-10 secretion associated with visceral leishmaniasis.

B J Holaday1.   

Abstract

This study examined the role and source of endogenous interleukin-10 (IL) secretion in visceral leishmaniasis (VL). The amounts of endogenous and Leishmania specific IL-10 and interferon-gamma (IFN) secreted by peripheral blood mononuclear cells (PBMC) from VL patients were compared. The correlation coefficient between endogenous IL-10 secretion and Leishmania specific IFN-gamma was -0. 77, suggesting a major role for endogenous IL-10 secretion in VL. The effects of CD4+ and CD8+ T cell clones, isolated from a treated VL patient, on IL-10 secretion were assayed by mixing the clones with autologous, inactivated PBMC. The CD8+ clones mediated increased levels of IL-10 secretion in the presence of PBMC alone suggesting that CD8+ T cells may mediate endogenous IL-10 secretion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10733741     DOI: 10.1590/s0074-02762000000200013

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  5 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Mixed inflammatory/regulatory cytokine profile marked by simultaneous raise of interferon-gamma and interleukin-10 and low frequency of tumour necrosis factor-alpha(+) monocytes are hallmarks of active human visceral Leishmaniasis due to Leishmania chagasi infection.

Authors:  V Peruhype-Magalhães; O A Martins-Filho; A Prata; L De A Silva; A Rabello; A Teixeira-Carvalho; R M Figueiredo; S F Guimarães-Carvalho; T C A Ferrari; J Van Weyenbergh; R Correa-Oliveira
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

Review 3.  Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects.

Authors:  Om Prakash Singh; Shyam Sundar
Journal:  Front Immunol       Date:  2014-06-26       Impact factor: 7.561

Review 4.  Cytokines: Key Determinants of Resistance or Disease Progression in Visceral Leishmaniasis: Opportunities for Novel Diagnostics and Immunotherapy.

Authors:  Alti Dayakar; Sambamurthy Chandrasekaran; Suresh V Kuchipudi; Suresh K Kalangi
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

5.  Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble Leishmania antigens and modified with a TNFα-mimicking peptide or monophosphoryl lipid A confers protection against experimental visceral leishmaniasis.

Authors:  Maritsa Margaroni; Maria Agallou; Evita Athanasiou; Olga Kammona; Costas Kiparissides; Catherine Gaitanaki; Evdokia Karagouni
Journal:  Int J Nanomedicine       Date:  2017-08-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.